For medtech start-ups
Learn how early Notified Body dialogues can help you verify regulatory assumptions, make regulatory decisions based on business needs and communicate regulatory credibility clearly to investors.
From regulatory assumptions to business risk
For many medtech start-ups, engaging with a Notified Body can feel formal, complex and difficult to approach. As a result, regulatory assumptions are often left untested until they have already influenced product development, funding plans or commercial claims.
This white paper explains how early Notified Body dialogue can enable start-ups and investors identify regulatory business risks earlier, build a clearer view of regulatory maturity and make better-informed decisions on the path to CE certification and beyond.
What you will learn
- How unverified regulatory assumptions can turn into business risks for medtech start-ups
- Why early Notified Body dialogue can support regulatory credibility and understanding the requirements
- How regulatory and clinical roadmaps can be verified before key business decisions are fixed
- How intended purpose and risk class determine commercial success
- What regulatory maturity means in relation to runway and investor confidence
- How early dialogues can help increase investor confidence and mitigate regulatory business risks
Who this white paper is for
For investors
Understand how early dialogue can provide evidence that a start-up is actively identifying and managing regulatory business risks before they affect timelines, funding or growth.
Malte Knowles Schmidt
Global Portfolio Manager Medical Device Software, AI and Cybersecurity